All of the following cause inhibition of CYP3A except
## Core Concept
The cytochrome P450 3A (CYP3A) enzyme is a crucial component of the cytochrome P450 family, involved in the metabolism of approximately half of all prescribed drugs. Inhibitors of CYP3A can lead to increased levels of these drugs, potentially causing toxicity. Understanding which compounds inhibit or induce CYP3A is essential for managing drug interactions.
## Why the Correct Answer is Right
Ritonavir is a well-known potent inhibitor of CYP3A. It is often used in combination with other protease inhibitors in the treatment of HIV/AIDS, partly because of its ability to boost the levels of these drugs by inhibiting their metabolism via CYP3A. This property makes ritonavir a valuable component of antiretroviral therapy.
## Why Each Wrong Option is Incorrect
* **Option A:** Ketoconazole is an antifungal agent that is known to be a potent inhibitor of CYP3A. Its use can lead to significant drug interactions with substrates of CYP3A.
* **Option B:** Erythromycin is a macrolide antibiotic that also inhibits CYP3A. This can result in increased levels of drugs that are metabolized by CYP3A, potentially leading to toxicity.
* **Option D:** Clarithromycin, another macrolide antibiotic, is similar to erythromycin in that it can inhibit CYP3A, although its potency as an inhibitor may vary.
## Clinical Pearl / High-Yield Fact
A key point to remember is that when using potent inhibitors of CYP3A, dose adjustments of drugs that are substrates for this enzyme may be necessary to avoid toxicity. For example, the combination of statins (which are metabolized by CYP3A) with potent CYP3A inhibitors like ketoconazole or ritonavir can increase the risk of statin-induced myopathy.
## Correct Answer: .